Trial Profile
Untreated IIIB/IV period with the EGFR mutation in the gene, phase II study of Gefitinib and the pemetrexed / bevacizumab combination maintenance therapy after Gefitinib and the cisplatin / pemetrexed / bevacizumab combination induction therapy for non-squamous epithelium non-small cell lung cancer of the latter recurrence
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2016
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Bevacizumab; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 21 Feb 2015 New trial record